NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Like Adam Feuerstein, I took the opportunity to ask ChatOn some questions regarding the DCVax cancer vaccine platform (DCVax-L and DCVax Direct), and “I just love it”:



I asked ChatOnif a dendritic cell cancer vaccine like DCVax is tumor / tissue agnostic, and could be effective and used against solid tumor cancers of all or most types, regardless of which organ the tumor is located in (brain tumors, ovarian, lung, breast, pancreatic, colon, etc.)?

At first, ChatOn said that the dendritic cell cancer vaccine would be tissue agnostic if it was designed to attack a specific biomarker or gene mutation. But, I reminded ChatOn that the FDA and EMA has issued recent tissue agnostic guidance that said not only could targeting a specific biomarker or gene mutation could make a drug or treatment tissue agnostic, but the drug / treatment mechanism of action, across all cancer types could make it tissue agnostic:



Then, ChatOn agreed and said this:



Here is what ChatGPT said:



Here is an excerpt from the FDA’s new guidance on what makes a new drug or treatment tissue agnostic:



The mechanism of action (MOA) for DCVax-L was detailed in the JAMA article that published the trial results:



https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

NWBio literally says on its website that the DCVax vaccine platform is designed to treat all or most solid tumor cancers, regardless of which organ the cancer tumor is located in. That is basically the literal definition of a tissue agnostic treatment: